Extendicare Inc.
EXE.TOTSXHealthcare● Active
$33.14
+$1.07(+3.34%)
Market Cap$3.1B
P/E Ratio—
52W High$35.62
52W Low$12.12
Extendicare Inc. (EXE.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EXE.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.42
Est. $0.21 · +101.0%
Revenue
$0.47B
Est. $0.44B · +6.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 6-Quarter EPS Beat Streak
EXE.TO reports quarterly as a TSX-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.40 | — | — | — | $0.57B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.21 | $0.42 | +101.0% | $0.47B | $0.44B | +6.4% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.26 | $0.29 | +8.0% | $0.46B | $0.49B | -4.8% |
| ▲ Q4 FY2025 | Nov 11, 2025 | $0.20 | $0.28 | +42.6% | $0.44B | $0.42B | +5.5% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.18 | $0.37 | +105.0% | $0.38B | $0.42B | -7.7% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.16 | $0.18 | +7.5% | $0.37B | $0.43B | -12.4% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $0.18 | $0.23 | +27.8% | $0.39B | $0.37B | +5.3% |
| — Q4 FY2024 | Nov 12, 2024 | — | $0.19 | — | $0.36B | $0.38B | -5.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.42
EPS Est.
$0.21
EPS Surpr.
+101.0%
Revenue
$0.47B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.29
EPS Est.
$0.26
EPS Surpr.
+8.0%
Revenue
$0.46B
Q4 FY2025
Nov 11, 2025Beat
EPS Actual
$0.28
EPS Est.
$0.20
EPS Surpr.
+42.6%
Revenue
$0.44B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.37
EPS Est.
$0.18
EPS Surpr.
+105.0%
Revenue
$0.38B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.18
EPS Est.
$0.16
EPS Surpr.
+7.5%
Revenue
$0.37B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.23
EPS Est.
$0.18
EPS Surpr.
+27.8%
Revenue
$0.39B
Q4 FY2024
Nov 12, 2024
EPS Actual
$0.19
EPS Est.
—
EPS Surpr.
—
Revenue
$0.36B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.32 | $0.32 | $0.32 | 1 |
| Q3 FY2028 | $0.30 | $0.30 | $0.30 | 1 |
| Q2 FY2028 | $0.27 | $0.27 | $0.27 | 1 |
| Q1 FY2028 | $0.25 | $0.25 | $0.25 | 1 |
| Q4 FY2027 | $0.31 | $0.31 | $0.31 | 1 |
| Q3 FY2027 | $0.28 | $0.28 | $0.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.7B | $0.7B | $0.7B | 1 |
| Q3 FY2028 | $0.6B | $0.6B | $0.6B | 1 |
| Q2 FY2028 | $0.6B | $0.6B | $0.6B | 1 |
| Q1 FY2028 | $0.6B | $0.6B | $0.6B | 1 |
| Q4 FY2027 | $0.6B | $0.6B | $0.6B | 1 |
| Q3 FY2027 | $0.6B | $0.6B | $0.6B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +101.0% | $30.17 | $30.20 | +0.10% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +8.0% | $24.49 | $24.15 | -1.39% |
| ▲ Q4 FY2025 | Nov 11, 2025 | +42.6% | $16.14 | $15.94 | -1.24% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +105.0% | $12.69 | $12.66 | -0.24% |
| ▲ Q2 FY2025 | May 6, 2025 | +7.5% | $14.45 | $14.55 | +0.69% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +27.8% | $11.76 | $11.63 | -1.11% |
| — Q4 FY2024 | Nov 12, 2024 | — | $9.57 | $9.48 | -0.94% |
| — Q3 FY2024 | Aug 12, 2024 | — | $7.73 | $7.62 | -1.42% |
Q2 FY2026+0.10%
Report Date
May 7, 2026
EPS Beat/Miss
+101.0%
Price Before
$30.17
Price After
$30.20
Q1 FY2026-1.39%
Report Date
Feb 26, 2026
EPS Beat/Miss
+8.0%
Price Before
$24.49
Price After
$24.15
Q4 FY2025-1.24%
Report Date
Nov 11, 2025
EPS Beat/Miss
+42.6%
Price Before
$16.14
Price After
$15.94
Q3 FY2025-0.24%
Report Date
Aug 6, 2025
EPS Beat/Miss
+105.0%
Price Before
$12.69
Price After
$12.66
Q2 FY2025+0.69%
Report Date
May 6, 2025
EPS Beat/Miss
+7.5%
Price Before
$14.45
Price After
$14.55
Q1 FY2025-1.11%
Report Date
Feb 27, 2025
EPS Beat/Miss
+27.8%
Price Before
$11.76
Price After
$11.63
Q4 FY2024-0.94%
Report Date
Nov 12, 2024
EPS Beat/Miss
—
Price Before
$9.57
Price After
$9.48
Q3 FY2024-1.42%
Report Date
Aug 12, 2024
EPS Beat/Miss
—
Price Before
$7.73
Price After
$7.62
Avg Beat Reaction-0.53%
Beat Rate6 / 8 quarters
Largest Move-1.42% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EXE.TO ends December
Extendicare Inc. (EXE.TO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.42 — beating the analyst consensus of $0.21 by +101.0%. EXE.TO has beaten EPS estimates for 6 consecutive quarters. The next EXE.TO earnings date is expected around September 1, 2026.
Each quarter, investors track EXE.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EXE.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EXE.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EXE.TO earnings · 5 questionsExtendicare Inc.'s next earnings report is expected around September 1, 2026. EXE.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EXE.TO historically reports after market close (AMC).
EXE.TO earnings datewhen is EXE.TO earningsEXE.TO next earnings datewhen does EXE.TO report earningsEXE.TO earnings calendar
▸ Source: FMP · Extendicare Inc. SEC filings · US GAAP · Extendicare Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026